Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


United And Divided: Natco's Patent Challenge On Revlimid Leads Dr. Reddy's To Up Its Pitch

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Natco Pharma's patent challenge earlier this month over Celgene's blockbuster multiple myeloma drug Revlimid (lenalidomide) has led India's Dr. Reddy's Labs to fast-track its own development of the product, which was brought under a restricted distribution plan by U.S. FDA due to its risky profile

You may also be interested in...

India's Natco Eyes Generic For Celgene's Mega Brand Revlimid; Will REMS Scuttle The Move?

MUMBAI - Although U.S.-headquartered Celgene succeeded last year in preventing India's Dr. Reddy's Labs from conducting bioequivalence studies on its fast-growing multiple myeloma drug Revlimid (lenalidomide) - due to risk management and restricted distribution issues - it may have a much harder fight on its hands now

Will REMS Delay Generics? Dr. Reddy’s Revlimid Petition May Help Determine Answer

Dr. Reddy's is urging U.S. FDA to start now to define a policy that assures that restricted distribution programs and other types of Risk Evaluation and Mitigation Strategies won't be used to block generic drug approvals

India’s Dr. Reddy’s, Natco Strike Deal To Target Abraxane And Several Other Oncology Drugs

MUMBAI - Highly profitable generic drugs - mainly in the oncology segment - are the latest targets for Indian pharmaceutical companies as margins rapidly shrink on commoditized off-patent drugs in the U.S. and several other markets. With that objective, India's Dr. Reddy's Labs and Natco, a company specializing in oncology drugs have signed a deal for the development, manufacture and supply of a basket of value added generic oncology drugs




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts